Try our Advanced Search for more refined results

Method Patent, Lilly Drug Patent Can Coexist, Fed. Circ. Rules

By Ryan Davis (August 24, 2012, 8:37 PM EDT) -- An earlier patent on a method of deriving the chemotherapy drug Alimta does not render Eli Lilly & Co.'s later patent on the drug itself invalid for double patenting, the Federal Circuit ruled Friday, rejecting arguments by Teva Pharmaceutical Industries Ltd. and other generics makers....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections

Law Firms

Companies

Patents

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!